Cancer Advisor

Different cancers behave differently because they are driven by different genetic mutations . The same gene (like KRAS or TP53) can mean very different things depending on whether it appears in lung, colon, or pancreatic cancer . This guide translates those patterns into a clear, patient-focused mutation map . 1. Lung Cancer (NSCLC): The most mutation-driven solid tumor Non-small cell lung cancer (NSCLC) is one of the most genetically profiled cancers in the world. Treatment is now heavily guided by mutation testing. Key mutations in lung cancer EGFR (most clinically actionable) One of the most important mutations in lung adenocarcinoma More common in: Non-smokers Women Asian populations What it means: Tumor growth is driven by an overactive EGFR signaling pathway Cancer depends heavily on this “growth antenna” Treatment implication: Highly responsive to EGFR-targeted therapies Often first-line treatment in EGFR-positive disease Examples include EGFR tyrosine kinase inhibitors Patient ...

What immunotherapy actually means (in simple terms) Immunotherapy is a type of cancer treatment that helps your immune system recognize and attack cancer cells more effectively . Instead of directly killing cancer cells like chemotherapy or radiation, immunotherapy: “Re-trains” immune cells Removes the brakes that cancer uses to hide Strengthens immune attack signals In normal conditions, your immune system can detect abnormal cells. But cancer evolves ways to hide, disable immune responses, or “turn off” immune signals. Immunotherapy reverses this hiding mechanism. Why immunotherapy is considered a breakthrough Before immunotherapy, most treatments focused on: Surgery (removing tumors) Chemotherapy (killing fast-dividing cells) Radiation (damaging tumor DNA) These approaches are still essential—but immunotherapy introduced a major shift: 👉 It can create long-term immune memory against cancer That means in some patients: Tumors shrink dramatically Cancer may remain controlled for year...

Introduction: The Shift From Description to Prediction For the past two decades, cancer research has been dominated by one central idea: If we understand the genetic mutations driving a tumor, we can target them precisely. This gave rise to precision oncology —a paradigm built on genomic sequencing, biomarker testing, and targeted therapies. But a hard truth has emerged: Patients with identical mutations often have wildly different outcomes . This inconsistency has fueled the rise of predictive oncology —a more advanced approach that aims to forecast treatment response before therapy begins, powered by Artificial intelligence and multi-layered biological data. 1. What Is Precision Oncology? Precision oncology focuses on matching therapies to tumor biology . Core principle: Treat the mutation, not just the tumor location. According to the National Cancer Institute, precision medicine uses genetic or molecular profiling to guide therapy selection, improving outcomes in selected patient ...

Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. However, we acknowledge that robust clinical trials are needed to provide more conclusive scientific evidence. Contents: Editor's Preface Introduction Fenbendazole and Ivermectin Case Series Compilation (alphabetical) Breast Cancer Success Stories  (...